After many failures, two KRAS inhibitors have shown exciting results against the G12C KRAS variant, which occurs in nearly half of NSCLC KRAS mutations: sotorasib (Amgen) and adagrasib (Mirati Therapeutics). This evidence concerns the gene KRAS and non-small cell lung carcinoma.